Navigation Links
Martek Announces Second Quarter 2009 Financial Results
Date:6/3/2009

er totaled $4.3 million, compared with $2.9 million a year ago. This increase was primarily due to a change in the timing of orders from one existing customer. While the Company expects to continue reducing the scope of its contract manufacturing activities, Martek will, at times, provide such services to both existing and new customers if reasonable profit margins are expected and there is no impact to the Company's higher margin nutritional oils business.

Gross Margin and Operating Expenses

Overall gross margin for the second quarter of fiscal 2009 was 42.3%, an increase over the 41.2% gross margin realized in the second quarter of fiscal 2008. The improvement resulted largely from ARA cost reductions and increased capacity utilization at Martek's manufacturing facilities.

Research and development expenses in the second quarter of fiscal 2009 were $7.2 million, an increase of 5% over the corresponding quarter of last year. Research and development as a percentage of revenue increased to 7.7% from 7.5% in the prior year's second quarter. The increase relates primarily to development work focusing on offerings for new markets and broadening the array of foods and beverages in which the Company's life'sDHA(TM) can be incorporated. The Company continues to expect quarter-to-quarter fluctuations in research and development expenses mainly due to the timing of outside services, including third-party clinical trial services.

During the second quarter of fiscal 2009, selling, general and administrative expenses ("SG&A") were $12.9 million, or 13.9% of revenue, a decrease from $14.2 million or 15.7% of revenue in last year's second quarter. The Company continues to closely manage its SG&A spending levels. Martek expects that for fiscal 2009, SG&A will be lower than fiscal 2008 levels on both a percentage of revenue and absolute dollar basis reflecting the cost ma
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Martek Announces Third Quarter 2007 Financial Results
3. Martek Announces Addition of lifesDHA(TM) to Entire Bellybar(TM) Line of Nutrition Bars
4. Martek Signs Multi-Year Infant Formula License and Supply Agreement with Alter Farmacia
5. Marteks lifesDHA(TM) Featured in New Beech-Nut(R) DHA Plus Baby Food and Cereals
6. Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinovas Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements
7. Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International
8. Marteks lifesDHA(TM) Featured in Dalco Foods Wellness Line Meat Products
9. Martek Announces Settlement of Class Action Lawsuit
10. Pocket Rocket Juice from Australias Boost Juice Features 700 mg of Marteks lifesDHA(TM)
11. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... ... rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich , has ... from March 4th - 6th, the 2016 (a previous announcement had stated the dates ... take participants from the basic training and fundamentals of nasal surgery through the most ...
(Date:7/3/2015)... CT (PRWEB) , ... July 03, 2015 , ... Smoothies ... home is a good blender and easily accessible, quality ingredients. Aurora Natural is proud ... smoothie for an added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... great for documenting memories. , Almost every smartphone has an incredibly powerful camera built ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Mississippi. The premium frozen yogurt chain was listed as #22 on the Inc. 500 ... Avenue, New Albany, MS 38652, will have a grand opening event on July 4, ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... Edwards (D-Md.) for her introduction of the Stop Overdose Stat (S.O.S.) Act of ... Senator Jack Reed (D-R.I.), this Act seeks to decrease drug overdose – especially ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetfrog Opens First Location in Mississippi 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3
... with colon cancer that has advanced beyond the early ... according to a recent study. In addition to an ... have an increased risk of cancer recurrence, at least ... outcomes and treatment-related side effects in colon cancer patients ...
... ovarian cancer in women at high risk for the ... of the risk reduction depends upon the type and ... rate of all gynecological cancer and few preventive or ... ovarian cancer is a family member who has been ...
... black cohosh is an effective way to relieve menopausal ... be safe for women with breast cancer or women ... School of Pharmacy at Duquesne University studied how the ... did not increase the incidence of new tumors but ...
... a gene mutation that may cause premature ovarian failure, or ... into, what researchers say, is a poorly understood condition. ,Premature ... 250,000 women in the United States. It is diagnosed in ... Investigators created mice that lack both copies of a gene ...
... hope for the millions of people throughout the world ... form of eczema marked by frequent, unpredictable relapses. It ... potent topical corticosteroid followed by a lower potency preparation ... of topical corticosteroids followed by a maintenance regimen using ...
... to give up many of the activities to which you ... not being able to go places that aren’t wheelchair accessible ... new research in Philadelphia brings paralyzed people a little closer ... something amazing happens to Les Kirk.,Instead of us doing it ...
Cached Medicine News:
(Date:7/3/2015)... DALLAS , July 3, 2015 ... report "Cardiac Monitoring & Cardiac Rhythm Management Market ... Output Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber ... published by MarketsandMarkets, the global Cardiac Monitoring (CM) ... poised to reach $26,646.5 Million by 2020 from ...
(Date:7/3/2015)... 2015 A global continuing medical ... and thyroid disorders in Latin America ... conference dedicated to these diseases.      (Logo: ... Manage Hypertension Online and Manage Thyroid ... EXCEMED - combine the world,s top expertise with ...
(Date:7/3/2015)... , July 3, 2015  Obsidian HDS, the ... an online service for the management of data on ... today that PharmaShine now includes the 2014 Open Payments ... Medicare Services on June 30. The data disclosed on ... transactions between industry and providers totaling $6.49 billion and ...
Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved ... from Exenatide Taken Twice a Day, SAN FRANCISCO, ... Eli Lilly and Company (NYSE: LLY ), and ... a 52-week open-label clinical,study that showed the durable efficacy ...
... VIEW, Calif., June 9 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R),alprazolam) ... not meet its two,primary endpoints, which were the ... panic attack and the effect of AZ-002 on ...
Cached Medicine Technology:After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
... Flat is designed for routine ... induction of posterior vitreous detachments. ... macula whole surgery, epiretinal membranes ... epiretinal membranes. Direct image lens ...
The Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens....
... and increased stereopsis, the Central Retinal ACS ... the equatorial regions. The Central Retinal is ... membrane peeling in proliferative vitreoretinopathy extending to ... ACS Vitrectomy Lenses from Volk can be ...
... patented ACS lenses offer the high resolution, ... the original clariVits. The simple two part ... its integrity during surgery. Simply autoclave, add ... then lock together for use. (ACS) AutoClave ...
Medicine Products: